[1] Borrow R, Alarcón P, Carlos J, et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection [J]. Expert Review of Vaccines, 2017, 16(4):1.
[2] Hamborsky J, Kroger A, Wolfe C, et al. Centers for Disease Control and Prevention: Epidemiology and prevention of vaccine-preventable diseases [J]. Washington, DC: Public Health Foundation, 2016, 18(3):1.
[3] Girard M P, Preziosi M P, Aguado M T, et al. A review of vaccine research and development: meningococcal disease [J]. Vaccine, 2006, 24(22):4692-4693.
[4] Blanchard-Rohner G, Snape M D, Kelly D F, et al. Seroprevalence and placental transmission of maternal antibodies specific for Neisseria meningitidis Serogroups A, C, Y and W135 and influence of maternal antibodies on the immune response to a primary course of MenACWY-CRM vaccine in the United Kingdom [J]. The Pediatric Infectious Disease Journal, 2013, 32(7):768-776.
[5] Michael B, Francesco B, Paolo C. Factors contributing to the immunogenicity of meningococcal conjugate vaccines [J]. Human Vaccines & Immunotherapeutics, 2016, 12(7):1808-1824.
[6] Cuello M, Cabrera O, Martinez I, et al. New meningococcal C polysaccharide-tetanus toxoid conjugate Physico-chemical and immunological characterization [J]. Vaccine, 2007, 25(10):1798-1805.
[7] Bardotti A, Averani G, Berti F, et al. Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases [J]. Vaccine, 2008, 26(18):2284-2296.
[8] 张营营, 李智华, 徐维明. 脑膜炎球菌多糖蛋白结合疫苗研究进展 [J]. 中国免疫学杂志, 2011, 27(12):1143-1149.
Zhang Y Y, Li Z H, Xu W M. Progress research of meningococcal polysaccharide conjugate vaccine [J]. Chinese Journal of Immunology, 2011, 27(12):1143-1149.
[9] Badahdah A M, Rashid H, Khatami A. Update on the use of meningococcal serogroup C CRM???-conjugate vaccine (Meningitec) against meningitis [J]. Expert Review of Vaccines, 2016, 15(1):9-29.
[10] 张娜, 吴丽洁, 赵俊,等. 溴化氰活化法和胺还原法制备的A群、C群脑膜炎球菌多糖蛋白结合物生化及免疫学特性比较 [J]. 中国新药杂志, 2016(21):2441-2445.
Zhang N, Wu L J, Zhao J, et al. Biochemical and immunological characteristics of group A and group C meningococcal polysaccharide-tetanus toxoid conjugates prepared by cyanogen bromide activation and amine reduction [J]. Chinese Journal New Drugs, 2016(21):2441-2445.
[11] An S J, Yoon Y K, Kothari S, et al. Physico-chemical properties of Salmonella typhi Vi polysaccharide-diphtheria toxoid conjugate vaccines affect immunogenicity [J]. Vaccine, 2011, 29(44):7618-7623.
[12] 郑佳, 朱向国, 刘刚,等. A群C群脑膜炎球菌多糖结合疫苗的免疫原性及免疫持久性观察 [J]. 中国生物制品学杂志, 2015, 28(7):707-710.
Zheng J, Zhu X G, Liu G, et al. Immunogenicity and immune persistence of groups A&C meningococcal polysaccharide conjugate vaccine [J]. Chinese Journal of Biologicals, 2015, 28(7):707-710.
[13] Gaertner H F, Offord R E. Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins [J]. Bioconjugate Chemistry, 1996, 7(1):38-39.
[14] Heath A A, Va?tilingom M, Ehrenhauser F S, et al. Determination of aldehydes and acetone in fog water samples via online concentration and HPLC [J]. Journal of Atmospheric Chemistry, 2015, 72(2):165-182.
[15] Sedlak J, Lindsay R H. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent [J]. Analytical Biochemistry, 1968, 25(1):192-205.
[16] 吴凯, 陈磊, 周红军,等. 肺炎链球菌18C型多糖结合物中游离多糖含量检测方法的建立 [J]. 中国生物制品学杂志, 2009, 22(9):930-932.
Wu K, Chen L, Zhou H J, et al. Development of A Method for Determination of Free Polysaccharide Content in Streptococcus pneumoniae Type 18C Polysaccharide Conjugate [J]. Chinese Journal of Biologicals, 2009, 22(9):930-932.
[17] 黄庆瑞. 基于化学修饰的脑膜炎多糖结合疫苗和结核分枝杆菌亚单位疫苗 [D]. 北京: 中国科学院研究生院(过程工程研究所), 2016: 76-77.
Huang Q R. Meningococcal polysaccharide conjugate vaccine and mycobacterial tuberculosis subunit vaccine based on chemical conjugation [D]. Beijing: Chinese Academy of Science (Institute of Process Engineering), 2016: 76-77.
[18] Ho M M, Mawas F, Bolgiano B, et al. Physico-chemical and immunological examination of the thermal stability of tetanus toxoid conjugate vaccines [J]. Vaccine, 2002, 20(29–30):3509-3522.
[19] Macdonald R A, Hosking C S, Jones C L. The measurement of relative antibody affinity by ELISA using thiocyanate elution [J]. Journal of Immunological Methods, 1988, 106(2):191-192.
[20] 张延龄, 张晖. 疫苗学 [M]. 北京: 科学出版社, 2006:346-355.
Zhang Y L, Zhang H. Vaccine [M]. Beijing: Science Press, 2006: 346-355.
[21] Geoghegan K F, Stroh J G. Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine [J]. Cheminform, 1992, 23(29):138-146.
[22] Bardotti A, Averani G, Berti F, et al. Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases [J]. Vaccine, 2008, 26(18):2284-2285.
[23] Gudlavalleti S K, Lee C H, Norris S E, et al. Comparison of Neisseria meningitidis serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide [J]. Vaccine, 2007, 25(46):7972-7980.
[24] Zhu Z Y, Pang W, Li Y Y, et al. Effect of ultrasonic treatment on structure and antitumor activity of mycelial polysaccharides from Cordyceps gunnii [J]. Carbohydrate Polymers, 2014, 114:12.
[25] Br?ker M, Dull PM, Rappuoli R, et al. Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages [J]. Vaccine, 2009, 27(41):5574-5580.
[26] Moore S L, Uitz C, Ling C C, et al. Epitope Specificities of the Group Y and W-135 Polysaccharides of Neisseria meningitides [J]. Clinical & Vaccine Immunology Cvi, 2007, 14(10):1311.
|